Страна: Велика Британія
мова: англійська
Джерело: VMD (Veterinary Medicines Directorate)
Feline calicivirus, Feline leukemia virus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Boehringer Ingelheim Vetmedica Gmbh
QI06AH10
Feline calicivirus, Feline leukemia virus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Powder and solvent for suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cats
Live and Inactivated Viral Vaccine
Authorized
2005-02-23
Revised: March 2023 AN: 01446/2022 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCP FeLV lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml or 0.5 ml: Lyophilisate: ACTIVE SUBSTANCES: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ..... 10 4.9 CCID 50 1 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens . 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ........................... 10 3.5 CCID 50 1 EXCIPIENT: Gentamicin, at most......................................................................23 µg Solvent: ACTIVE SUBSTANCE: FeLV recombinant canarypox virus (vCP97) ............................... 10 7.2 CCID 50 1 1 cell culture infective dose 50%. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Lyophilisate: homogeneous beige pellet. Solvent: clear colourless liquid with presence of cell debris in suspension. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs, - against leukaemia to prevent persistent viraemia and clinical signs of the related disease. Revised: March 2023 AN: 01446/2022 Page 2 of 6 Onsets of immunity: - Rhinotracheitis, calicivirus and panleucopenia components: 1 week after primary vaccination course. - Feline leukaemia component: 2 weeks after primary vaccination course. Duration of immunity: - Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination. - Feline Leukaemia component: 1 year after the last re-vaccination. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNING Прочитайте повний документ